IRX4 Transcription Factor: New Research Insights on Colorectal Cancer Treatment Targets

　　1.Research Background and Significance

　　Colorectal cancer(CRC)is one of the most deadly malignant tumors worldwide.A key reason for treatment failure in many patients is chemotherapy resistance or reduced chemotherapy sensitivity,especially in advanced-stage patients.IRX4,as a transcription factor expressed in various tissues,has been found to be associated with the progression of multiple cancers.This study focuses on the potential role of IRX4 in colorectal cancer,which holds significant clinical importance.

　　2.IRX4 Expression in Colorectal Cancer Tissues

　　Research shows that IRX4 expression is significantly downregulated in colorectal cancer tissues and cell lines.Its expression level is negatively correlated with tumor invasion depth and poor prognosis,meaning less IRX4 expression may indicate more severe tumors and worse prognosis.

　　This finding has been confirmed through a series of detection methods including immunofluorescence staining,reverse transcription quantitative polymerase chain reaction,and Western blot experiments.This provides important clues for further understanding the pathogenesis of colorectal cancer.

　　3.Therapeutic Effects of IRX4 Overexpression

　　In vitro cell experiments demonstrate that IRX4 overexpression can inhibit the proliferation,migration,and invasion capabilities of colorectal cancer cells while promoting cell apoptosis.This means cancer cells that were growing uncontrollably can be effectively suppressed by IRX4.

　　Additionally,IRX4 overexpression can enhance the sensitivity of colorectal cancer cells to oxaliplatin(OXA)chemotherapy.During chemotherapy,IRX4 can play a synergistic role,allowing oxaliplatin to achieve better therapeutic effects.

　　4.Mechanism of Action Analysis

　　From a molecular mechanism perspective,IRX4 overexpression can significantly inhibit TNF-α-induced NF-κB transcriptional activity and suppress NF-κB p65 nuclear translocation in colorectal cancer cells.This is equivalent to cutting off the signaling pathways for cancer cell growth,preventing them from receiving growth instructions.

　　Furthermore,combined treatment of oxaliplatin with IRX4 overexpression can significantly reduce epidermal growth factor receptor(EGFR)levels and phosphorylation levels of its downstream signaling molecules,further inhibiting cancer cell growth and survival.

　　5.Clinical Application Prospects

　　In summary,IRX4 may serve as a prognostic biomarker and therapeutic target for colorectal cancer.It can regulate colorectal cancer progression and chemotherapy sensitivity by inhibiting the NF-κB/EGFR pathway,providing new ideas and potential treatment directions for improving colorectal cancer chemotherapy efficacy.

　　With continuous advances in medical research,more therapeutic targets similar to IRX4 will be discovered in the future.Patients are advised to understand cancer scientifically,seek medical attention promptly if related symptoms occur,and actively cooperate with treatment.